Total Tumour-Burden Dosimetry in Patients Undergoing 177 Lu-PRRT (EANM 2026) - Sep 29, 2026 - Abstract #OP-155; Pres time: Oct 18, 2026; 03:00 PM - 04:30 PM; Location: Hall B; "Aim/Introduction: There is an increasing interest for tumour dosimetry in 177Lu peptide receptor radionuclide therapy (PRRT), requiring tumour delineation in [177Lu]Lu-DOTA-TATE SPECT-images... The automated segmentation method was found valuable for streamlined identification and delineation of total tumour burden in SPECT-images of 177Lu-PRRT patients. Its applicability was demonstrated in a post-hoc analysis of clinical-trial data."
Clinical • Neuroendocrine Tumor • Oncology • Solid Tumor
|
|
S. Curkic Kapidzic 1, 2; J. Gustafsson 1; E. Larsson 2; C. Warfvinge 3, 4; P. Asp 3, 4; A. Gålne 5; K. Sjögreen Gleisner 1
|